Araris Biotech AGZurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership is to develop next-generation antibody–drug conjugates (ADCs). While Araris itself is now Japanese-owned – a wholly owned subsidiary of Taiho Pharmaceutical, part of the Otsuka Group – its research activities remain firmly rooted in Zurich. That presence was highlighted last year when the Strüngmann brothers, German billionaire twins, awarded a prize to the company’s founders.
Freepik.comThe Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration and option agreement with a total potential value of up to CHF 265 million. This is good news for Memo, while CSL, following substantial job cuts including in Marburg, could also use some different headlines for a change.
After more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or the United States has yet been shown to slow or modify disease progression. Against that backdrop, 4Moving Biotech (4MB) is betting that a familiar drug class, GLP-1 receptor agonists, can succeed where others have fallen short.
© Bayer LeverkusenBayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class example from Leverkusen. Whether the data will be sufficient for regulatory approval remains to be seen.
Aerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025.
Two of the U.K.’s largest life sciences real-estate projects have moved forward within days of each other, with major expansion plans unveiled in London and Cambridge as both regions look to add new laboratory and research capacity.
Stockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab).
Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.
adobe stock photos - Michael Derrer Fuchs Novartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has therefore issued a cautious outlook for 2026. The CEO’s high, bonus-driven remuneration has sparked debate.
Leyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies.